When I look at ACADIA Pharmaceuticals, I see a company that has already crossed one of biotechnology’s most dangerous borders: it has stopped being a clinical-stage promise factory and become a commercial business. That distinction matters. ACADIA has two approved products, growing revenue, positive net income, and enough cash to fund a serious development program without immediately passing a collection plate among shareholders. It also has a pipeline capable of changing the company’s long-term value—assuming, as always, that biology agrees to cooperate. That last condition deserves emphasis. Biotechnology investors have a charming habit of treating every clinical program as an approved blockbuster temporarily inconvenienced by the absence of evidence. A compound enters Phase 2, management displays an enormous patient population, and somebody multiplies that population by the annual treatment cost. By lunchtime, the drug is supposedly worth $12 billion. Actual drug development is less...
For years, I viewed ACADIA Pharmaceuticals as a company with one commercial engine and an uncomfortable amount of hope attached to everything else. That engine was NUPLAZID, the first and only drug approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis. It gave ACADIA a real business, not merely a collection of laboratory ambitions. But it also made the investment story painfully concentrated. When one drug carries the company, every prescription trend, reimbursement change, patent dispute, and competitive threat begins to feel like a referendum on the entire enterprise. That is no longer the full story. DAYBUE, approved in 2023 for Rett syndrome, has become a meaningful second franchise. ACADIA now expects more than $1.2 billion in combined annual revenue from two approved medicines, has nearly $1 billion in cash and investments, and is generating quarterly profit while funding a broader neuroscience pipeline. The company has cross...